Assessment of perfusion deficit with early phases of [ 18 F]PI-2620 tau-PET versus [ 18 F]flutemetamol-amyloid-PET recordings.

Autor: Völter F; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Beyer L; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Eckenweber F; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Scheifele M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Bui N; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Patt M; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany., Barthel H; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany., Katzdobler S; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Palleis C; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Franzmeier N; Institute for Stroke and Dementia Research (ISD), Munich, Germany., Levin J; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Perneczky R; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.; Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK.; Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK., Rauchmann BS; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Sabri O; Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany., Hong J; Department of Radiology, University Hospital, LMU Munich, Munich, Germany., Cumming P; Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland.; School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia., Rominger A; Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland., Shi K; Department of Nuclear Medicine, Bern University Hospital, Bern, Switzerland., Bartenstein P; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Brendel M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany. matthias.brendel@med.uni-muenchen.de.; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. matthias.brendel@med.uni-muenchen.de.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. matthias.brendel@med.uni-muenchen.de.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Apr; Vol. 50 (5), pp. 1384-1394. Date of Electronic Publication: 2022 Dec 27.
DOI: 10.1007/s00259-022-06087-y
Abstrakt: Purpose: Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can serve for the A/T/N classification of neurodegenerative diseases. Recent studies showed that the early, perfusion-weighted phases of amyloid- or tau-PET recordings serve to detect cerebrometabolic deficits equally to FDG-PET, therefore providing a surrogate of neuronal injury. As such, two channels of diagnostic information can be obtained in the setting of a single PET scan. However, there has hitherto been no comparison of early-phase amyloid- and tau-PET as surrogates for deficits in perfusion/metabolism. Therefore, we undertook to compare [ 18 F]flutemetamol-amyloid-PET and [ 18 F]PI-2620 tau-PET as "one-stop shop" dual purpose tracers for the detection of neurodegenerative disease.
Methods: We obtained early-phase PET recordings with [ 18 F]PI-2620 (0.5-2.5 min p.i.) and [ 18 F]flutemetamol (0-10 min p.i.) in 64 patients with suspected neurodegenerative disease. We contrasted global mean normalized images (SUVr) in the patients with a normal cohort of 15 volunteers without evidence of increased pathology to β-amyloid- and tau-PET examinations. Regional group differences of tracer uptake (z-scores) of 246 Brainnetome volumes of interest were calculated for both tracers, and the correlations of the z-scores were evaluated using Pearson's correlation coefficient. Lobar compartments, regions with significant neuronal injury (z-scores <  - 3), and patients with different neurodegenerative disease entities (e.g., Alzheimer's disease or 4R-tauopathies) served for subgroup analysis. Additionally, we used partial regression to correlate regional perfusion alterations with clinical scores in cognition tests.
Results: The z-scores of perfusion-weighted images of both tracers showed high correlations across the brain, especially in the frontal and parietal lobes, which were the brain regions with pronounced perfusion deficit in the patient group (R = 0.83 ± 0.08; range, 0.61-0.95). Z-scores of individual patients correlated well by region (R = 0.57 ± 0.15; range, 0.16-0.90), notably when significant perfusion deficits were present (R = 0.66 ± 0.15; range, 0.28-0.90).
Conclusion: The early perfusion phases of [ 18 F]PI-2620 tau- and [ 18 F]flutemetamol-amyloid-PET are roughly equivalent indices of perfusion defect indicative of regional and lobar neuronal injury in patients with various neurodegenerative diseases. As such, either tracer may serve for two diagnostic channels by assessment of amyloid/tau status and neuronal activity.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje